Adam Maeder
Stock Analyst at Piper Sandler
(3.63)
# 807
Out of 4,969 analysts
94
Total ratings
50.79%
Success rate
7.74%
Average return
Main Sectors:
Stocks Rated by Adam Maeder
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RBOT Vicarious Surgical | Maintains: Neutral | $8.5 → $7 | $5.84 | +19.86% | 8 | Aug 13, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $233 → $150 | $85.60 | +75.23% | 15 | Aug 5, 2025 | |
| RMD ResMed | Maintains: Neutral | $248 → $270 | $269.21 | +0.29% | 4 | Aug 1, 2025 | |
| EW Edwards Lifesciences | Maintains: Overweight | $83 → $90 | $81.22 | +10.81% | 16 | Jul 25, 2025 | |
| ISRG Intuitive Surgical | Reiterates: Overweight | $575 → $595 | $441.18 | +34.87% | 20 | Jul 23, 2025 | |
| RXST RxSight | Maintains: Neutral | $18 → $10 | $8.88 | +12.61% | 2 | Jul 9, 2025 | |
| SGHT Sight Sciences | Maintains: Neutral | $3.5 → $4 | $3.80 | +5.26% | 1 | Jun 18, 2025 | |
| NSPR InspireMD | Maintains: Overweight | $4.5 → $4 | $2.41 | +65.98% | 4 | May 12, 2025 | |
| TCMD Tactile Systems Technology | Downgrades: Neutral | $25 → $14 | $13.24 | +5.74% | 3 | May 6, 2025 | |
| ABT Abbott Laboratories | Reiterates: Overweight | $133 → $145 | $132.18 | +9.70% | 3 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $20 → $21 | $16.28 | +28.99% | 2 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $7 → $8 | $3.27 | +144.65% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 → $20 | $5.81 | +244.23% | 8 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $5 | $2.71 | +84.50% | 2 | Mar 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $10 → $18 | $1.49 | +1,108.05% | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $104 → $99 | $56.58 | +74.97% | 3 | May 5, 2022 |
Vicarious Surgical
Aug 13, 2025
Maintains: Neutral
Price Target: $8.5 → $7
Current: $5.84
Upside: +19.86%
Inspire Medical Systems
Aug 5, 2025
Maintains: Overweight
Price Target: $233 → $150
Current: $85.60
Upside: +75.23%
ResMed
Aug 1, 2025
Maintains: Neutral
Price Target: $248 → $270
Current: $269.21
Upside: +0.29%
Edwards Lifesciences
Jul 25, 2025
Maintains: Overweight
Price Target: $83 → $90
Current: $81.22
Upside: +10.81%
Intuitive Surgical
Jul 23, 2025
Reiterates: Overweight
Price Target: $575 → $595
Current: $441.18
Upside: +34.87%
RxSight
Jul 9, 2025
Maintains: Neutral
Price Target: $18 → $10
Current: $8.88
Upside: +12.61%
Sight Sciences
Jun 18, 2025
Maintains: Neutral
Price Target: $3.5 → $4
Current: $3.80
Upside: +5.26%
InspireMD
May 12, 2025
Maintains: Overweight
Price Target: $4.5 → $4
Current: $2.41
Upside: +65.98%
Tactile Systems Technology
May 6, 2025
Downgrades: Neutral
Price Target: $25 → $14
Current: $13.24
Upside: +5.74%
Abbott Laboratories
Apr 17, 2025
Reiterates: Overweight
Price Target: $133 → $145
Current: $132.18
Upside: +9.70%
May 22, 2024
Maintains: Hold
Price Target: $20 → $21
Current: $16.28
Upside: +28.99%
Mar 6, 2024
Reiterates: Overweight
Price Target: $7 → $8
Current: $3.27
Upside: +144.65%
Mar 6, 2024
Maintains: Overweight
Price Target: $15 → $20
Current: $5.81
Upside: +244.23%
Mar 6, 2023
Maintains: Overweight
Price Target: $6 → $5
Current: $2.71
Upside: +84.50%
Jan 6, 2023
Upgrades: Overweight
Price Target: $10 → $18
Current: $1.49
Upside: +1,108.05%
May 5, 2022
Maintains: Overweight
Price Target: $104 → $99
Current: $56.58
Upside: +74.97%